Insights

Gathering insights about CITEC…

Similar companies to CITEC

CITEC Tech Stack

CITEC uses 8 technology products and services including Open Graph, F5 BIG-IP, Microsoft 365, and more. Explore CITEC's tech stack below.

Open Graph
Content Management System
F5 BIG-IP
Data Security
Microsoft 365
Email
Google Fonts API
Font Scripts
jQuery
Javascript Libraries
Lightbox
Javascript Libraries
Bootstrap
UI Frameworks
Contact Form 7
Web Platform Extensions

Media & News

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA.
Nov 06, 2023 | www.globenewswire.com
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows:
Sep 13, 2023 | www.globenewswire.com
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress.
Aug 10, 2023 | www.globenewswire.com
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023 – The International Liver CongressTM taking place June 21-24 in Vienna, Austria. HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB). The data will be presented as a poster at EASL on Saturday, June 24 (Poster ID: SAT-198), by Eleanor Barnes, Professor of Hepatology and Experimental Medicine at Oxford University.
Jun 21, 2023 | www.globenewswire.com
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.
Apr 05, 2023 | investorplace.com
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.
Oct 03, 2022 | www.globenewswire.com
Vaccitech to Present at Upcoming September Investors Conferences
OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.
Sep 07, 2022 | www.globenewswire.com

CITEC's Email Address Formats

CITEC uses at least 1 format(s):

CITEC Email Formats	Example	Percentage
First.Last@citec.com.au	John.Doe@citec.com.au	94%
FLast@citec.com.au	JDoe@citec.com.au	5%
Last@citec.com.au	Doe@citec.com.au	1%

Frequently Asked Questions

What is CITEC's stock symbol?

CITEC is a publicly traded company; the company's stock symbol is VACC.

What is CITEC's official website and social media links?

CITEC's official website is citec.com.au and has social profiles on LinkedIn.

What is CITEC's NAICS code?

CITEC's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does CITEC have currently?

As of December 2025, CITEC has approximately 505 employees across 6 continents, including OceaniaEuropeAsia. Key team members include Engagement Partner: P. A.Co-Owner: E. C.Owner: C. G.. Explore CITEC's employee directory with LeadIQ.

What industry does CITEC belong to?

CITEC operates in the IT Services and IT Consulting industry.

What technology does CITEC use?

CITEC's tech stack includes Open GraphF5 BIG-IPMicrosoft 365Google Fonts APIjQueryLightboxBootstrapContact Form 7.

What is CITEC's email format?

CITEC's email format typically follows the pattern of First.Last@citec.com.au. Find more CITEC email formats with LeadIQ.

When was CITEC founded?

CITEC was founded in 1964.

CITEC

Q: What is CITEC's official website and social media links?

CITEC's official website is citec.com.au. CITEC has social profiles on LinkedIn.

Q: How many employees does CITEC have currently?

CITEC has approximately 505 employees.

Q: What technology does CITEC use?

CITEC's tech stack includes jQuery Migrate, Yoast SEO, jQuery, TrackJS, Google Fonts API.

IT Services and IT ConsultingQueensland, Australia501-1000 Employees

CITEC is the primary technology service provider for the Queensland Government delivering both whole-of-government and agency specific ICT services. CITEC's range of ICT services include: security, data centre, cloud, network, managed IT and professional services.